TRU-016 represents an innovative therapeutic targeting the CD79b molecule , a critical component of the B-cell receptor. This engineered monoclonal exhibits a affinity to CD79b antigen, leading https://prbookmarkingwebsites.com/story29339068/otlertuzumab-tru-016-a-deep-dive-into-the-anti-cd79b-antibody